Dec 1, 2025 07:01AM
Dec 1, 2025 07:00AM
Sep 2, 2025 08:00AM
Sep 2, 2025 08:00AM
Sep 2, 2025 08:00AM
Aug 8, 2025 08:00AM
May 14, 2025 08:00AM KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
Mar 31, 2025 08:00AM
Nov 12, 2024 08:00AM
Aug 6, 2024 08:00AM
May 14, 2024 04:05PM
Mar 29, 2024 08:00AM
Nov 13, 2023 08:00AM
Aug 4, 2023 08:00AM KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
May 9, 2023 08:00AM
Mar 3, 2023 08:02AM
Mar 3, 2023 08:00AM
Mar 3, 2023 08:00AM
Nov 8, 2022 08:00AM
Nov 8, 2022 08:00AM
Aug 11, 2022 07:00AM Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 11, 2022 07:00AM
May 16, 2022 07:00AM
May 16, 2022 07:00AM
May 3, 2022 08:03AM
May 3, 2022 08:00AM
May 3, 2022 08:00AM
May 1, 2022 09:00AM Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting
May 1, 2022 09:00AM
Mar 29, 2022 07:04AM
Mar 29, 2022 07:00AM
Mar 29, 2022 07:00AM
Mar 8, 2022 08:10AM
Mar 8, 2022 08:00AM
Mar 8, 2022 08:00AM Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare
Dec 15, 2021 06:25AM
Nov 18, 2021 04:01PM
Nov 18, 2021 04:01PM
Nov 15, 2021 08:47AM
Nov 15, 2021 08:47AM
Nov 15, 2021 08:45AM
Nov 15, 2021 08:45AM Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Dise
Nov 15, 2021 08:45AM
Nov 16, 2020 07:08AM
Nov 16, 2020 07:00AM
Apr 3, 2018 08:00AM
Mar 5, 2018 08:00AM
Nov 13, 2017 08:07AM
Nov 13, 2017 08:00AM Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer
Nov 7, 2017 07:30AM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All